Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Acute Kidney Injury Market Size Changed, over the years?
Significant growth has been observed in the acute kidney injury market in the past few years. An escalation from $5.37 billion in 2024 to $5.74 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%, is predicted. The upward trend during the historical interval is linked to rising instances of chronic illnesses, an expanding elderly population, a surge in hospital-acquired infections, growing consciousness about kidney health, and breakthroughs in critical care medicine.
How Much Will the Acute Kidney Injury Market Be Worth in 2029?
The market for acute kidney injury is slated to witness robust expansion in the years to come. The anticipated market value by 2029 would amount to $7.39 billion, with a compound annual growth rate (CAGR) of 6.5%. Factors contributing to the predicted growth span from the escalating incidence of sepsis, an escalating need for personalized treatment procedures, consistent enhancements in government healthcare initiatives, increasing investments in healthcare in budding markets, as well as a pronounced emphasis on individualized medicine and regenerative treatments. Some major trends set to shape the market in the forecast period comprise wearable dialysis devices, the role of artificial intelligence in enhancing treatment, portable systems for renal replacement therapy, advancements in continuous renal replacement therapy (CRRT), remote patient monitoring, and the integration of telemedicine.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21079&type=smp
Which is the Largest Company in the Acute Kidney Injury Market?
Major companies operating in the acute kidney injury market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Medical Co. Ltd., Teva Pharmaceutical Industries Ltd., Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd., Quark Pharmaceuticals Inc., Kringle Pharma Inc., Aptabio Therapeutics Inc., Alexion Pharmaceuticals Inc., Alloksys Life Sciences B.V., AM-Pharma B.V., Arch Biopartners Inc., Guard Therapeutics International AB
What Are the Main Market Drivers in the Acute Kidney Injury Industry?
The rise in diabetes cases is predicted to fuel the expansion of the acute kidney injury market. Diabetes, a collective term for a set of metabolic disorders, is characterized by elevated glucose levels, either due to insufficient insulin production or cellular resistance to insulin. The increasing incidence of diabetes is propelled by factors such as escalating obesity rates, unhealthy eating habits, inactive lifestyles, an aging population, and improved awareness and diagnosis. Acute kidney injury instigates metabolic and inflammatory alterations which can affect insulin resistance and glucose balance, underlining a complicated dynamic that could influence the development and management of diabetes. As an illustration, the UK’s Office for Health Improvement & Disparities reported in March 2024 that between March 2022 and March 2023, the proportion of people with type 1 diabetes who received all eight recommended care processes rose by 22%, and for type 2 diabetes, the increase was 21%. Moreover, the percentage reaching target HbA1c levels grew to 37.9%, the highest figure ever noted by the National Diabetes Audit (NDA). Thus, the escalating prevalence of diabetes is stimulating the acute kidney injury market’s growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21079&type=smp
How Is the Acute Kidney Injury Market Segments Structured?
The acute kidney injury market covered in this report is segmented –
1) By Injury: Pre-Renal Kidney Injury, Post-Renal Kidney Injury, Intrinsic Kidney Injury
2) By Treatment Type: Dialysis, Drug Therapy, Urinary Implants
3) By End User: Hospitals, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Pre-Renal Kidney Injury: Hypovolemia, Heart Failure-Related Injury, Sepsis-Induced Injury, Renal Artery Stenosis, Hepatorenal Syndrome
2) By Post-Renal Kidney Injury: Ureteral Obstruction, Bladder Outlet Obstruction, Prostate Enlargement (Benign Prostatic Hyperplasia), Kidney Stones, Tumors Affecting Urinary Tract
3) By Intrinsic Kidney Injury: Acute Tubular Necrosis (ATN), Acute Interstitial Nephritis (AIN), Glomerulonephritis, Vasculitis, Rhabdomyolysis-Induced Injury
What Strategic Trends Are Transforming the Acute Kidney Injury Market?
Leading companies engaged in the acute kidney injury (AKI) industry are placing their emphasis on securing regulatory approvals in order to expand their product offerings and present innovative treatment solutions. The term “regulatory approvals” refers to the formal permission granted by authorities such as the FDA or EMA. This permission allows a product to be promoted and sold once it has met definite standards of safety, effectiveness, and quality. An example of this is the FDA approval received by Mission Therapeutics Ltd., a UK-based biotech firm, in December 2023. The approval authorized the initiation of a Phase II clinical trial for its main asset, MTX652, aimed at AKI in high-risk patients following a heart operation. The goal of the MTX652 is to act on key pathways relevant to kidney damage and recovery, mitigating inflammation, impeding further damage to the kidney, and assisting in recuperation. A remarkable aspect of this trial is its exploration of innovative therapeutic mechanisms to deal with the core molecular triggers of AKI, potentially devising more impactful treatment strategies than current approaches. The Phase II trial will scrutinize the safety, effectiveness, and pharmacokinetics of MTX652, providing invaluable data that might propel more widespread clinical use and possible subsequent approval.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/acute-kidney-injury-global-market-report
Which Global Regions Offer the Highest Growth in the Acute Kidney Injury Market?
North America was the largest region in the acute kidney injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute kidney injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21079
This Report Delivers Insight On:
1. How big is the acute kidney injury market, and how is it changing globally?
2. Who are the major companies in the acute kidney injury market, and how are they performing?
3. What are the key opportunities and risks in the acute kidney injury market right now?
4. Which products or customer segments are growing the most in the acute kidney injury market?
5. What factors are helping or slowing down the growth of the acute kidney injury market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
